Related by context. All words. (Click for frequent words.) 82 Phase III clinical 81 Phase III trials 79 clinical trials 77 Phase IIb trial 77 pivotal Phase III 76 clinical trial 74 Phase 2b clinical 74 Phase III 74 Phase IIa trial 73 Phase IIb clinical 73 Phase IIb 72 Phase 2b study 72 Phase Ib 72 phase IIb 72 Phase 2b trial 71 Phase IIb trials 71 Phase IIa clinical 71 Phase IIa 71 phase IIb clinical 70 Phase 2a trial 70 phase IIa clinical 69 Phase IIa trials 69 Phase 2a clinical 69 Phase Ib clinical 69 Phase IIa clinical trials 69 phase IIa 69 phase IIb trial 68 Phase 2b 68 Phase 1b clinical 68 pivotal Phase 68 Phase IIb clinical trials 68 Phase 2a 68 Phase III pivotal 68 registrational 67 preclinical 67 Phase IIIb clinical 67 Phase 1b trial 67 confirmatory Phase III 67 Phase 1b 66 dirucotide 66 confirmatory Phase 3 66 investigational drug 65 Asentar 65 Phase II 65 JAK inhibitor 65 Corlux 65 phase 2a 65 midstage studies 64 Phase 2b clinical trials 64 Dacogen injection 64 Phase #b/#a 64 randomized Phase 64 phase Ib clinical 64 APEX PD 64 IND enabling 64 phase Ib 64 FOLOTYN ® 64 dose escalation trial 64 preclinical studies 64 MBP# [001] 64 PRX # 64 placebo controlled Phase 64 COMFORT II 64 CDP# 63 TELINTRA 63 Phase Ib study 63 AQ4N 63 Phase Ib clinical trials 63 mipomersen 63 Phase Ia 63 forodesine 63 investigational 63 Allovectin 7 63 BCX# 63 GLP toxicology studies 63 teduglutide 63 Omigard 62 Diamyd ® 62 Phase Ib II 62 multicenter Phase II 62 GALNS 62 registrational trial 62 clinical pharmacology studies 62 dose escalation study 62 diabetic neuropathic pain 62 Fodosine 62 BLA submission 62 CB2 selective receptor agonist 62 EOquin 62 PDE4 inhibitor 62 Phase IIB 62 PSN# [002] 62 CEQ# 62 Phase IIIb 62 SUCCEED trial 62 Phase 1a 62 midstage clinical trials 62 TBC# 62 NDA submission 62 Mipomersen 62 oral ridaforolimus 62 PREOS 62 OvaRex ® MAb 62 phase IIb study 62 Amrubicin 62 IIa trial 62 Phase III Clinical Trials 61 SinuNase TM 61 investigational compound 61 multicenter Phase 61 Marqibo 61 Civacir 61 TELCYTA 61 lorvotuzumab mertansine 61 Alzhemed TM 61 alvimopan 61 ATryn ® 61 Aurexis 61 Allovectin 7 R 61 dose cohorts 61 Phase IIIb study 61 dirucotide MBP# 61 AEG# 61 Memryte 61 ProLindac 61 Onalta ™ 61 oral deforolimus 61 PEG PAL 61 Marketing Authorization Application MAA 61 RSD# oral 61 Myocet 61 Amigal 61 ALN TTR# 61 MEK inhibitor 61 Pivotal Trial 61 Phase 2a clinical trials 61 New Drug Application 61 elotuzumab 61 Urocidin 61 SNT MC# 61 midstage trials 61 dose escalation Phase 60 glufosfamide 60 Phase #b/#a trial 60 OvaRex R 60 PrevOnco 60 talactoferrin 60 RhuDex ® 60 INCB# [001] 60 IMGN# 60 cell lymphoma CTCL 60 Phase 1a clinical 60 huC# DM4 60 IMA# 60 PLK1 SNALP 60 ZYBRESTAT 60 pegloticase 60 Tarceva TM 60 tivozanib 60 Nexavar sorafenib 60 reslizumab 60 BLA filing 60 Aryplase 60 vosaroxin 60 Loramyc R 60 multiple ascending dose 60 HGS# 60 Marketing Authorization Application 60 acyclovir Lauriad R 60 Rhucin 60 albinterferon alfa 2b 60 Vicinium TM 60 Rhucin ® 60 QNEXA ® 60 CoFactor 60 IND submission 60 pharmacokinetic studies 60 initiate Phase IIb 60 Icatibant 60 ADVANCE PD 60 placebo controlled Phase III 60 Veronate 60 satraplatin 60 valopicitabine 60 crofelemer 60 KNS # 60 severe hypercholesterolemia 60 Exherin TM 60 Lupuzor 60 Phase #b/#a clinical 60 Biologics License Application 60 Iluvien ® 60 Plicera 60 lomitapide 60 PS# [001] 59 Marketing Authorisation Application 59 Microplasmin 59 Sulonex 59 non alcoholic steatohepatitis 59 Reverset 59 MOZOBIL 59 EFAPROXYN 59 Zytiga 59 Panzem R 59 Dapagliflozin 59 Zenvia Phase III 59 Riquent 59 ecallantide 59 BAY #-# 59 HCV protease inhibitor 59 hypoxia activated prodrug 59 oral prodrug 59 REMOXY ® 59 lintuzumab SGN 59 ATL# [001] 59 OncoVEX GM CSF 59 sunitinib malate 59 VEGF Trap 59 Fx #A 59 alogliptin 59 cutaneous T cell 59 ocrelizumab 59 Clevudine 59 double blinded placebo 59 IL# PE#QQR 59 dosing cohorts 59 octreotide implant 59 dose cohort 59 placebo controlled clinical 59 YONDELIS 59 multicenter Phase III 59 Virulizin R 59 placebo controlled 59 bazedoxifene 59 miconazole Lauriad ® 59 bardoxolone 59 cardio renal 59 Proxinium TM 59 Bronchitol 59 Phase III Clinical Trial 59 HuMax CD4 59 Investigational Device Exemption IDE 59 ATryn R 59 clinical trials SGN 59 RDEA# 59 Soliris TM eculizumab 59 Oncoscience AG 59 CCR5 antagonist 59 alvespimycin 59 phase III isavuconazole 59 Gabapentin GR 59 MAA submission 59 rALLy trial 59 ILUVIEN ® 59 Ozarelix 59 Investigational 59 BRIM3 59 Factor VIIa 59 pitavastatin 59 ALTU 59 orally administered 59 Fibrillex TM 59 ruxolitinib 59 omacetaxine 59 TRANSDUR Sufentanil 59 placebo controlled clinical trials 59 PREOS R 59 axitinib 59 rALLy clinical trial 59 docetaxel Taxotere R 59 Phase III placebo controlled 59 Phase III Pivotal 59 oral calcitonin 59 liprotamase 59 ALN RSV# 58 LEUKINE 58 rindopepimut 58 Pivotal Phase III 58 regadenoson 58 opioid induced bowel dysfunction 58 dalbavancin 58 cannabinor 58 Canvaxin 58 T Pred 58 ulimorelin 58 daclizumab 58 PANVAC VF 58 multicenter clinical 58 PDX pralatrexate 58 Dalbavancin 58 mertansine 58 Augment Injectable 58 Archexin 58 CORLUX 58 GSK# [002] 58 Daclizumab 58 T DM1 58 budesonide foam 58 ApoB SNALP 58 LymphoStat B 58 omacetaxine mepesuccinate 58 sorafenib tablets 58 CHAMPION PCI 58 tiapamil 58 Cleviprex TM clevidipine 58 betrixaban 58 Nimotuzumab 58 ICA # 58 candidate AQ4N 58 registrational studies 58 MAXY alpha 58 Ixempra 58 Ophena 58 Phenoptin 58 targeted radiotherapeutic 58 StemEx 58 Troxatyl 58 AzaSite Plus 58 TYZEKA 58 Zelrix 58 Cethromycin 58 Mycograb 58 virus HCV protease inhibitor 58 INDs 58 oral methylnaltrexone 58 clofarabine 58 Clolar 58 Nexavar ® 58 IIa clinical 58 eltrombopag 58 RELOVAIR ™ 58 antibody MAb 58 Laquinimod 58 Sebivo 58 NGX# 58 Ceflatonin R 58 Proellex TM 58 pharmacokinetic PK study 58 Onco TCS 58 StaphVAX 58 MGCD# [001] 58 IDX# 58 Traficet EN 58 Dyloject TM 58 preclinical toxicology 58 StaphVAX R 58 Raptiva R 58 antisense drug 58 double blind placebo 58 tolevamer 58 Cloretazine ® 58 APF# 58 LEP ETU 58 HspE7 58 Augment TM 58 Personalized Immunotherapy 58 visilizumab 58 PD LID 58 Azilect ® 58 INCB# [002] 58 rNAPc2 58 diarrhea predominant irritable 58 obatoclax 58 Onalta 58 ITAX 58 NUVIGIL 58 Oglemilast 58 ofatumumab HuMax CD# 58 Cethrin 58 MKC# MT 58 Zerenex 58 MAGE A3 ASCI 58 Triolex 58 Zalbin 58 Relovair 58 IIa clinical trial 58 AGILECT R 58 Quinamed 58 belinostat 58 Phase IIb Trial 58 midstage clinical 58 EOquin TM 58 tremelimumab 58 Cloretazine R VNP#M 58 KRN# 58 PEG Interferon lambda 58 FUSILEV ® 58 Panzem 58 L BLP# 58 bicifadine 58 CYT# potent vascular disrupting 58 histone deacetylase HDAC inhibitor 58 REMOXY R 58 Azedra 58 Actilon 58 Cellegesic 58 ketolide antibiotic 58 BrachySil 58 single ascending dose 58 nalbuphine ER 58 #D#C# 58 Prodarsan ® 58 Nebido 58 TOCOSOL Paclitaxel 58 generation purine nucleoside 58 NP2 Enkephalin 58 Phase #/#a 58 APD# 58 Tarvacin TM 58 Phase #/#a trial 58 IV APAP 58 investigational pan BCR 57 cutaneous T 57 Nuvion 57 EDEMA3 57 pertuzumab 57 LymphoStat B TM 57 picoplatin 57 Fodosine TM 57 BARACLUDE R 57 ZADAXIN ® 57 cangrelor 57 phase IIb III 57 Phase 1b clinical trials 57 Safinamide 57 Loramyc ® 57 pivotal bioequivalence 57 AA amyloidosis 57 R#/MEM # 57 Ruconest 57 Cannabinor 57 SILENOR TM 57 Phase Ib IIa 57 Rescula 57 torezolid phosphate 57 methylnaltrexone 57 AEGR 57 Medidur TM FA 57 nalmefene 57 Shigamabs ® 57 metastatic hormone refractory 57 PROMACTA 57 European Sepsis Trial 57 carfilzomib 57 investigational hepatitis C 57 Cimzia TM 57 ANCHOR trial 57 EndoTAG TM -1 57 relapsed multiple myeloma 57 corneal transplant rejection 57 pharmacokinetic 57 Pimavanserin 57 Phase III confirmatory 57 ALN PCS 57 tramiprosate Alzhemed TM 57 SinuNase 57 Probuphine 57 AeroLEF TM 57 Board DSMB 57 FlutiformTM 57 Vicriviroc 57 Hyphanox 57 Plenaxis TM 57 dyskinesia PD LID 57 Biologics License Application BLA 57 Preotact 57 telaprevir 57 Flutiform TM 57 ISIS # 57 dose escalation clinical 57 Alocrest 57 Insegia 57 randomized Phase IIb 57 apaziquone 57 Phase III randomized controlled 57 ThermoDox R 57 PNP inhibitor 57 relapsed refractory multiple myeloma 57 Iloperidone 57 AeroLEF 57 RG# [001] 57 Pirfenidone 57 Ferumoxytol 57 Ocrelizumab 57 Ereska 57 pediatric glioma 57 relapsing remitting multiple sclerosis 57 integrase inhibitor 57 NO# [002] 57 Omnitarg 57 Phase 57 ADX# 57 Moxatag 57 subcutaneous formulation 57 Onconase 57 etanercept Enbrel 57 HCV SPRINT 57 Altropane 57 HuMax CD# 57 forodesine hydrochloride 57 Diamyd R 57 TACI Ig 57 selective androgen receptor modulator 57 trastuzumab DM1 T DM1 57 sNDA submission 57 recombinant biopharmaceutical 57 Parkinson disease levodopa induced 57 blinatumomab 57 rheumatoid arthritis psoriatic arthritis 57 zanolimumab 57 SUTENT 57 Rhucin R 57 Ophena TM 57 ixabepilone 57 Tyrima 57 Genasense ® 57 deforolimus 57 Phase IIb III 57 Dextofisopam 57 ANA# 57 blinded placebo controlled 57 Androxal TM 57 Solazed 57 Cetrorelix 57 MAP# 57 multicenter randomized placebo controlled 57 Amoxicillin PULSYS 57 anticancer compound 57 platforms GVAX 57 dacetuzumab 57 MNTX 57 ADAGIO study 57 HepeX B 57 Annamycin 57 AP# [003] 57 Augment Bone Graft 57 celgosivir 57 candidates bavituximab 57 huN# DM1 57 BENLYSTA 57 SUPPRELIN R LA 57 Firazyr 57 VNP#M 57 GED aPC 57 Synavive 57 synthetic retinoid 57 docetaxel Taxotere ® 57 Loramyc 57 intranasal formulation 57 blind placebo controlled 57 sumatriptan DosePro 57 Zingo TM 57 Rezular 57 elagolix 57 ELACYT 57 Orazol 57 PF # [002] 57 Phase III Trial 57 randomized placebo controlled 57 POSIDUR TM ELADUR TM 57 SYMMETRY trial 57 TG MV 57 HuMax EGFr 57 AZD# 57 albiglutide 57 Cintredekin Besudotox 57 investigational oral 57 Allovectin 7 ® 57 opioid induced constipation 57 aclidinium bromide 57 investigational antiplatelet agent 57 prostone 57 tolerability 57 ridaforolimus 57 LibiGel Phase III 57 ThGRF 57 leading oral taxane 56 Ridaforolimus 56 OncoGel 56 mGluR5 negative 56 AVE# 56 sodium thiosulfate STS 56 Velcade bortezomib 56 Voraxaze 56 SEBIVO 56 Excellarate TM 56 tezampanel NGX# 56 acyclovir Lauriad ® 56 Vernakalant 56 Aurora kinase inhibitor 56 Azixa 56 sorafenib Nexavar 56 Oracea TM 56 QuatRx 56 Zenvia ™ 56 danoprevir 56 Cerimon 56 AIMM trial 56 Vascular Wrap TM 56 ionotropic glutamate receptor antagonists 56 Cimzia ® certolizumab pegol 56 ENRICH trial 56 Valtropin 56 Puricase 56 OncoVex 56 LibiGel ® 56 CR# vcMMAE 56 MEK inhibitor RDEA# 56 Locteron 56 telbivudine 56 Soliris eculizumab 56 ancrod 56 PXD# 56 Sunovion 56 Panzem R NCD 56 pralatrexate 56 injectable formulation 56 rhC1INH 56 Inhalation Solution 56 Emselex 56 toremifene 56 OLpur TM H2H 56 TMC# [002] 56 IMC A# 56 CLIRS trial 56 PRTX 56 TAXUS Element Stent System 56 Phase IIb Clinical Trial 56 Reolysin 56 controlled multicenter 56 Leukine 56 liposomal formulation 56 Solazed TM 56 dose escalation 56 ALN TTR 56 Actemra tocilizumab 56 Viramidine 56 Kynapid 56 ELADUR 56 dexpramipexole 56 neratinib 56 AZILECT R 56 HQK 56 AZILECT ® 56 Phase IIb kidney transplant 56 Iluvien 56 Bicifadine 56 randomized controlled Phase 56 Aflibercept 56 trastuzumab DM1 56 HGS ETR1 56 Hepatocellular Carcinoma HCC 56 AZX# 56 myelofibrosis 56 Azedra TM 56 CD# CEA 56 Sym# 56 Raptiva ® 56 investigational protease inhibitor 56 teriflunomide 56 Relistor 56 PRT# 56 SAR# [004] 56 FOLOTYN 56 personalized immunotherapy 56 opioid bowel dysfunction 56 ONCONASE 56 Locteron ® 56 Preotact R 56 Relivar 56 Alpharadin 56 incyclinide 56 GAMMAGARD 56 ganetespib 56 TRISENOX 56 DPP4 inhibitor 56 CINTREDEKIN BESUDOTOX 56 symptomatic BPH 56 cetrorelix 56 ONGLYZA ™ 56 Elagolix 56 YONDELIS R 56 fostamatinib 56 BioSTAR R 56 JZP 56 Campath ® 56 refractory metastatic colorectal cancer 56 Pivotal Study 56 PEG INTRON 56 Clofarabine 56 refractory gout 56 ozarelix 56 receptor tyrosine kinase inhibitor 56 hormone refractory prostate cancer 56 Surfaxin LS 56 RSD# 56 ALN VSP 56 pafuramidine 56 arzoxifene 56 Darusentan 56 UPLYSO 56 forodesine HCl 56 Bepreve 56 Roche PEGASYS R 56 JZP 6 56 Staccato loxapine 56 solanezumab 56 ThermoDox ® 56 HCD# [002] 56 Allovectin 7 r 56 Anturol 56 nonclinical studies 56 Sutent sunitinib 56 lymphoma CTCL 56 QLT# 56 Cardio Vascu Grow 56 afamelanotide 56 PrevOnco ™ 56 clevudine 56 voreloxin 56 BYDUREON 56 humanized monoclonal antibody 56 TRANSDUR ® 56 CRD5 56 Hepatitis C HCV 56 velaglucerase alfa 56 PEP# [003] 56 BRIM2 56 Acetavance 56 Spiegelmer ® 56 inhaled formulation 56 LUVENIQ 56 VitiGam 56 Oral NKTR 56 ularitide 56 metastatic sarcomas 56 Pazopanib 56 Virulizin 56 atrasentan 56 Lymphoseek ® 56 SparVax TM 56 multicenter phase 56 velafermin 56 DC Bead 56 denufosol 56 ONTAK 56 Torisel 56 LY# [003] 56 granulated mesalamine 56 DU #b 56 faropenem 56 Lu AA# 56 faropenem medoxomil 56 Phase III HEAT 56 New Drug IND 56 ATHX 56 mapatumumab 56 balsalazide tablet 56 compound INCB# 56 Zolinza 56 Glybera 56 ezogabine 56 vinflunine 56 CRx 56 ELND# 56 Prosaptide 56 Arcalyst 56 PROPEL trial 56 Omigard TM 56 pradefovir 56 IIb clinical trial 56 intravenous formulation 56 MOR# 56 cathepsin K inhibitor 56 voclosporin 56 AVN# [001] 56 Orphan Drug Status 56 ONCONASE R 56 TMC# C# 56 bapineuzumab 56 DURIN TM 56 Trimesta 56 Telavancin 56 XIENCE V Stent System 56 Glybera R 56 HCV RESPOND 2 56 investigational humanized monoclonal antibody 56 candidates Dyloject TM 56 senicapoc 56 Prednisporin TM 56 drug eluting coronary stent 56 Orathecin 56 LCP AtorFen 56 administered subcutaneously 56 Cutanea 56 ENDEAVOR IV 56 labial herpes 56 Gattex 56 BRAF inhibitor 56 Pivotal Phase 56 polymerase inhibitor 56 Ceplene TM 56 Preos 56 randomized double 56 Xanafide 56 orally bioavailable 56 Clinical trials 56 DAVANAT 56 blinded randomized placebo controlled 56 Acapodene 56 romidepsin 56 panitumumab Vectibix 56 oral formulation 56 laquinimod 56 brivaracetam 56 Junovan TM 56 adipiplon 56 apricitabine 56 MDV# 56 PEARL SC 56 RHUCIN 56 ASA# 56 active comparator 56 candidate Zenvia 55 ZYBRESTAT fosbretabulin 55 SEPET TM 55 MEND CABG 55 MIST II 55 ANTEGREN 55 FIRAZYR 55 Gemin X 55 Sapacitabine 55 fidaxomicin Phase 3 55 TLK# 55 NVA# 55 udenafil 55 dextofisopam 55 II Clinical Trial 55 mTOR inhibitor 55 clinical trials lintuzumab SGN 55 placebo controlled studies 55 viral kinetic 55 refractory APL 55 Evoltra 55 Xcytrin R 55 histamine dihydrochloride 55 dosing cohort 55 Tavocept 55 Neulasta ® 55 ospemifene 55 anidulafungin 55 Vectibix panitumumab 55 marketed pegylated interferons 55 Frova ® 55 6R BH4 55 rilonacept 55 IPLEX 55 tesetaxel 55 carcinogenicity study 55 investigational compounds 55 BRILINTA 55 Stedivaze 55 Marketing Authorisation Application MAA 55 including eniluracil ADH 55 cancer immunotherapies 55 THALOMID 55 Nasulin 55 Vivecon 55 Topical Interferon Alpha 2b 55 MORAb 55 PFO migraine 55 entinostat 55 Kamada AAT 55 topically applied SEPA 55 telaprevir VX 55 phase III ACCLAIM 55 ABSORB trial 55 Telaprevir 55 Zavesca R 55 Phase III psoriasis 55 HFA MDI 55 tesmilifene 55 Santhera 55 oncolytic virus therapy 55 vernakalant oral 55 maraviroc 55 vemurafenib 55 oral iron chelator 55 silodosin 55 DR Cysteamine 55 Nanobody 55 ABRAXANE TM 55 REVIVE Diabetes 55 intravenous acetaminophen 55 Uricase PEG 55 TKM ApoB 55 ELADUR ™ 55 IND Investigational New 55 ORENCIA ® 55 nimotuzumab 55 Shigamabs R 55 Anturol ® 55 Perifosine 55 rilpivirine 55 Nasdaq HALO 55 prGCD 55 ZEVALIN ® 55 Cimzia certolizumab pegol 55 tezampanel 55 SUVN 55 tanespimycin 55 TASKi2 55 FAME Study 55 randomized Phase III 55 OHR/AVR# 55 confirmatory clinical 55 BioNumerik 55 ProLindac TM 55 oral salmon calcitonin 55 Nasdaq RDEA 55 Tamibarotene 55 subcutaneously administered 55 multi kinase inhibitor 55 Stimuvax R 55 Acetavance TM 55 iloperidone 55 elacytarabine 55 PHX# 55 Menerba 55 Ketotransdel 55 injectable antibiotic 55 Diabetic Macular Edema DME 55 tamibarotene 55 GTC recombinant human 55 omega interferon 55 Theratope 55 evaluating tivozanib 55 oral taxane 55 luliconazole 55 zalutumumab 55 Stavzor 55 DermaVir Patch 55 otelixizumab 55 mitogen activated ERK kinase 55 isavuconazole 55 TRANSDUR ™ 55 Ceplene 55 thymalfasin 55 SILENOR 55 Prodarsan R 55 ORENCIA R 55 QAB# 55 enzastaurin 55 Anthim 55 GSK# [001] 55 OncoVEX 55 Genasense 55 peginesatide 55 LAF# 55 EnzymeRx 55 Golimumab 55 Carfilzomib 55 eprotirome 55 doxorubicin Transdrug ® 55 Linjeta TM 55 L Annamycin 55 HIV integrase inhibitor 55 thorough QT 55 dimebon 55 Alitretinoin 55 OMAPRO 55 randomized multicenter 55 OMNARIS HFA 55 superficial bladder cancer 55 ADVEXIN 55 hepatitis C HCV 55 Alinia 55 IMC #B 55 Jevtana 55 Intarcia 55 prokinetic agent 55 MYDICAR ® 55 StemEx R 55 IIa clinical trials 55 Empatic TM 55 Poly ICR 55 Keryx 55 anti CD3 monoclonal 55 Leukine ® 55 mesylate 55 erlotinib Tarceva ® 55 SYCREST 55 FavId 55 NeurogesX 55 alemtuzumab Campath 55 glucokinase activator 55 PSMA ADC 55 evaluating REVLIMID 55 Rhucin ® recombinant